Vertex Pharmaceuticals Incorporated ($VRTX) Stock Forecast: Up 8.0% Today

What is Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals (VRTX) is a renowned biotechnology company in the field of cystic fibrosis drugs. The company is broadening its range to include gene-editing therapies and non-opioid pain medication, with a primary emphasis on its renal franchise, especially the IgAN program.

Why is Vertex Pharmaceuticals Incorporated going up?

VRTX stock is up 8.0% on Feb 13, 2026 18:27

• Vertex Pharmaceuticals (VRTX) saw a notable upward trend in the market due to positive analyst evaluations and coverage, indicating substantial growth prospects in its renal pipeline and non-cystic fibrosis products.
• The company's impressive financial results in Q4 2025, showcasing significant revenue growth and successful product introductions, contributed to the upbeat market movement.
• Analysts are closely observing Vertex's kidney franchise and advancements in its non-opioid painkiller Journavx, expecting promising outcomes and sustained momentum in the upcoming period.
• The market's favorable reaction to Vertex's strategic foray into gene therapy and pain management, along with its strong performance in the core cystic fibrosis franchise, likely underpinned the positive trajectory of VRTX stock.

VRTX Price Chart

VRTX Technical Analysis

VRTX News

Oppenheimer Upgrades Vertex Pharmaceuticals (VRTX) to Outperform | VRTX Stock News

Oppenheimer has upgraded Vertex Pharmaceuticals (VRTX) to an "Outperform" rating with a price target of $540.00 USD. This upgrade follows several other positive analyst revisions for VRTX in early 2026. Vertex Pharmaceuticals is a biotechnology company known for its cystic fibrosis drugs, and it is expanding its portfolio into gene-editing therapies and non-opioid pain medication.

https://www.gurufocus.com/news/8615764/oppenheimer-upgrades-vertex-pharmaceuticals-vrtx-to-outperform-vrtx-stock-news

Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays

Barclays has initiated coverage on Vertex Pharmaceuticals (VRTX) with an Overweight rating and a $606 price target, highlighting the significant growth potential of its renal franchise, particularly the IgAN program. The firm believes the market currently "underappreciates" this pipeline, which is expected to deliver promising results early in 2026, mirroring the success of Vertex's cystic fibrosis operations. Barclays also noted that increased prescriptions and revenues from Journavx have been overlooked by the market.

https://www.insidermonkey.com/blog/vertex-pharma-vrtx-renal-pipeline-seen-as-major-growth-driver-by-barclays-1695137/

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2025 Earnings Call Transcript

Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 and full-year 2025 financial results, with total revenue reaching $3.2 billion in Q4, a 10% increase year-over-year, and $12 billion for the full year, growing 9%. The company discussed strong performance in its CF franchise, successful launches of KASJEVY and Gernavix, and progress in its emerging renal pipeline, particularly with Povatacept for IgA nephropathy. Vertex provided 2026 revenue guidance of $12.95 billion to $13.1 billion, expecting significant contributions from non-CF products.

https://www.insidermonkey.com/blog/vertex-pharmaceuticals-incorporated-nasdaqvrtx-q4-2025-earnings-call-transcript-1695410/

Vertex Pharma Q4 2025 Earnings Results

Vertex Pharmaceuticals reported strong financial performance for Q4 2025, driven by its cystic fibrosis treatments and expanding profitability. The company achieved approximately $3.19 billion in revenue for the quarter and an adjusted EPS of about $5.03, signaling significant growth. Vertex emphasized pipeline progress in gene therapy and pain management, anticipating continued momentum and diversified growth beyond cystic fibrosis in the coming years.

https://news.alphastreet.com/vertex-pharma-q4-2025-earnings-results/?utm_source=rss&utm_medium=rss&utm_campaign=vertex-pharma-q4-2025-earnings-results

All Eyes On Vertex’s Kidney Franchise, as Painkiller Journavx Tops Half a Million Scripts

Analysts are closely observing Vertex Pharmaceuticals' kidney disease portfolio, particularly the IgAN drug povetacicept, as its late-stage RAINIER study is progressing smoothly with data expected in the first half of 2026. While the company's nonopioid painkiller Journavx is seeing incremental growth, competition is heating up in the IgAN space. Vertex also plans to expand povetacicept's use into neurology for generalized myasthenia gravis, despite growing competition in that area.

https://www.biospace.com/business/all-eyes-on-vertexs-kidney-franchise-as-painkiller-journavx-tops-half-a-million-scripts

Trending Today

Sabre Corporation ($SABR) Stock Forecast: Up 5.6% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Up 5.2% Today

Bitcoin ($BTC) Crypto Forecast: Up 6.9% Today

CoStar Group Inc. ($CSGP) Stock Forecast: Down 11.5% Today

Albemarle Corporation ($ALB) Stock Forecast: Up 5.3% Today

First Solar Inc. ($FSLR) Stock Forecast: Down 13.1% Today

PayPal Holdings Inc. ($PYPL) Stock Forecast: Up 7.4% Today

Corning Incorporated ($GLW) Stock Forecast: Up 5.5% Today

10x Genomics, Inc. ($TXG) Stock Forecast: Up 5.1% Today

Saia Inc. ($SAIA) Stock Forecast: Down 5.2% Today

Vertex Pharmaceuticals Incorporated Price History

03.11.2025 - VRTX Stock was up 5.9%

• An upgrade from a major financial institution to an Overweight rating for Vertex's stock and an increase in the price target, driven by the potential of the kidney pipeline candidates Pove and Inaxaplin, have boosted investor confidence in the company's expansion into new treatment areas.
• The addition of Duncan McKechnie as the Executive Vice President and Chief Commercial Officer brings extensive experience in commercial operations to Vertex, potentially enhancing the company's global commercial strategies and market presence.
• Vertex's solid financial standing, positive results from clinical trials of its kidney therapy, and expectations of growth in revenue and earnings from 2025 to 2035 have all contributed to the positive market outlook for the stock.
• Despite concerns about the company's reliance on cystic fibrosis treatments and pricing challenges, investors are monitoring Vertex's valuation, growth projections, and research and development efforts to evaluate its potential for growth in the competitive pharmaceutical industry.

03.10.2025 - VRTX Stock was down 2.4%

• Despite outperforming the market over the past 15 years with an average annual return of 18.0%, Vertex Pharmaceuticals (VRTX) experienced a -1.23% decrease in stock price today.
• The decrease in stock price could be attributed to profit-taking by investors after a period of strong performance.
• Investors might be reacting to recent market conditions or specific news related to Vertex Pharmaceuticals, prompting the bearish movement.
• It's essential to monitor further developments to understand if this bearish trend is a short-term correction or a more prolonged shift in market sentiment towards Vertex Pharmaceuticals.

03.11.2025 - VRTX Stock was up 5.6%

• The appointment of Duncan McKechnie as Vertex Pharmaceuticals' Executive Vice President and Chief Commercial Officer likely instilled confidence in investors, indicating strong leadership and strategic vision within the organization.
• Akeso's ambitious research and development (R&D) objectives and successful endeavors with Ivonescimab may have had a positive influence on Vertex's stock performance, showcasing the competitive landscape and potential for groundbreaking advancements in the industry.
• The collaboration between Regeneron Pharmaceuticals and Tessera Therapeutics to collaborate on a gene therapy for a rare medical condition likely fostered optimism in the biotech field, indirectly benefiting Vertex amid the broader positive sentiment towards healthcare innovations.
• Despite a Zacks Rank #3 (Hold) recommendation for Vertex, the prevailing optimistic outlook for pharmaceutical firms and the industry's growth potential possibly contributed to the upward momentum in the company's stock.

03.11.2025 - VRTX Stock was up 6.3%

• VRTX stock surged by 6.2% following an upgrade to "Overweight" with a new price target of $516, driven by optimism surrounding the potential of Vertex's kidney drug pipeline, specifically Pove and Inaxaplin.
• The upgrade reflects confidence in Vertex's pipeline diversity and the shift towards valuing drugmakers based on long-term chronic disease solutions, beyond the traditional cystic fibrosis franchise.
• The appointment of Duncan McKechnie as the Executive Vice President and Chief Commercial Officer also signals strong leadership within the company, further boosting investor confidence in Vertex's strategic direction and commercial activities.
• Despite facing challenges in its cystic fibrosis business, Vertex's promising clinical trial data for its investigational kidney therapy, povetacicept, is expected to drive accelerated revenue and earnings growth between 2025 and 2035, positioning the company for long-term success in the pharmaceutical industry.

16.08.2025 - VRTX Stock was down 1.8%

• VRTX stock faced a notable decline, closing at $388.55, reflecting a -2% drop from the prior day.
• Although Vertex Pharmaceuticals has a historically strong performance, the recent decline in the market might be linked to profit-taking among investors.
• The broader market surge could have prompted some traders to redistribute their investments, resulting in a brief downturn in VRTX stock.
• Investors are advised to stay vigilant about forthcoming healthcare sector updates that could influence Vertex Pharmaceuticals' stock behavior.

04.10.2025 - VRTX Stock was up 0.5%

• VRTX had a strong bullish movement today.
• The company is expected to report higher Q3 earnings, with analysts revising their forecasts ahead of the earnings call.
• Over the past 15 years, Vertex Pharmaceuticals has significantly outperformed the market, showcasing an average annual return of 18.0%.
• Despite a slight -1.23% dip in stock price recently, the overall market sentiment remains positive for Vertex Pharmaceuticals.

13.01.2026 - VRTX Stock was up 8.0%

• Vertex Pharmaceuticals (VRTX) saw a notable upward trend in the market due to positive analyst evaluations and coverage, indicating substantial growth prospects in its renal pipeline and non-cystic fibrosis products.
• The company's impressive financial results in Q4 2025, showcasing significant revenue growth and successful product introductions, contributed to the upbeat market movement.
• Analysts are closely observing Vertex's kidney franchise and advancements in its non-opioid painkiller Journavx, expecting promising outcomes and sustained momentum in the upcoming period.
• The market's favorable reaction to Vertex's strategic foray into gene therapy and pain management, along with its strong performance in the core cystic fibrosis franchise, likely underpinned the positive trajectory of VRTX stock.

13.01.2026 - VRTX Stock was up 5.4%

• The notable surge in Vertex Pharmaceuticals' stock price can be attributed to its impressive Q4 2025 financial results, indicating a 10% revenue growth year-over-year and a favorable outlook for 2026.
• Investor confidence in the company has been reinforced by its emphasis on the cystic fibrosis segment, successful product launches including KASJEVY and Gernavix, and advancements in other areas such as the renal pipeline with a focus on Povatacept for IgA nephropathy.
• Analysts' generally positive outlook on Vertex Pharmaceuticals, as reflected in a high average 12-month price target and favorable expert opinions, has further bolstered the bullish market sentiment.
• The purchase of Vertex Pharmaceuticals shares by ING Groep NV and other institutional investors indicates a strong belief in the company's future growth potential, underlining the positive sentiment prevailing in the market.

30.08.2025 - VRTX Stock was down 1.2%

• The bearish movement in VRTX could be due to profit-taking by investors after a period of significant gains.
• The bullish analyst upgrades for other companies may have diverted attention and capital away from VRTX, leading to a decline in its stock price.
• Investors might be rotating out of biotech stocks like VRTX and into other sectors, following the shifting recommendations from top Wall Street analysts.
• Overall, the bearish movement in VRTX today could be a combination of sector rotation, profit-taking, and the influence of bullish sentiment on other stocks in the market.

06.00.2026 - VRTX Stock was up 5.2%

• Vertex Pharmaceuticals was upgraded by Wolfe Research from "peer perform" to "outperform," with a price target of $548, reflecting optimism about the company's future.
• The company exceeded quarterly earnings expectations, showing strong growth in EPS and revenue, indicating a solid financial performance and potential for further advancement.
• Institutional investors demonstrate continued enthusiasm for Vertex Pharmaceuticals despite insider selling, holding a considerable portion of the company's stock, potentially boosting market confidence.
• The bullish trend in Vertex Pharmaceuticals can be linked to Wolfe Research's upgrade, the company's impressive financial results, and the sustained interest from institutional investors, indicating a positive sentiment towards its growth prospects in the biopharmaceutical industry.

06.00.2026 - VRTX Stock was up 5.0%

• The company was upgraded from "peer perform" to "outperform" by Wolfe Research with a price target of $548, reflecting a positive outlook on its growth prospects.
• Vertex exceeded quarterly earnings estimates with $4.80 EPS and $3.08 billion in revenue, showing 11% year-over-year growth, which contributed to the bullish sentiment.
• Despite insider selling activity, institutional investors owning a significant portion of the company's stock indicate strong confidence in its future performance.
• The upgrade and positive earnings results likely fueled investor optimism and buying interest in Vertex Pharmaceuticals, driving the stock price higher.

21.00.2026 - VRTX Stock was up 5.0%

• Vertex Pharmaceuticals is a leading biotech company known for its strong cystic fibrosis franchise and innovative therapies. The stock had a bullish movement today amidst positive market sentiment.
• A prominent financial firm reduced its stake in VRTX, but insiders have been selling shares, indicating confidence in the company's performance.
• Analysts maintain a "Moderate Buy" rating with an average target price of $503.80, reflecting optimism in the stock's potential.
• The upcoming announcement of fourth-quarter and full-year 2025 financial results on February 12th creates anticipation and interest among investors.
• Despite recent mixed performance, the stock's undervaluation potential of up to 39% according to a discounted cash flow model could be driving investor interest and contributing to the bullish movement.